← back to search

Anders Lundin

AstraZeneca (Sweden) · SE
Area of research
Molecular Biology · Health, Toxicology and Mutagenesis
Research interest
Research interests include CRISPR and Genetic Engineering, Air Quality and Health Impacts, Genetic Neurodegenerative Diseases, and Pluripotent Stem Cells Research.
h-index
22
citations
1,637
works
53
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy
Nature Nanotechnology 2025cited by 62position: middledoi
Human iPS-Derived Astroglia from a Stable Neural Precursor State Show Improved Functionality Compared with Conventional Astrocytic Models
Stem Cell Reports 2018cited by 148position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

— · 1 papers (2025–2025)— · 1 papers (2018–2018)— · 1 papers (2025–2025)Louise Delsing · Tufts University1 papers (2018–2018)Jiaxu Hong · Fudan University1 papers (2025–2025)— · 1 papers (2018–2018)Alan Sabirsh · Advanced Pharma1 papers (2018–2018)Anna Herland · Science for Life Laboratory1 papers (2018–2018)Jianping Liu · Hebei Medical University1 papers (2025–2025)Henrik Zetterberg · Indian Institute of Science Bangalore1 papers (2018–2018)— · 1 papers (2025–2025)— · 1 papers (2025–2025)Xujiao Zhou · Fudan University1 papers (2025–2025)Anna Falk · Lund University1 papers (2018–2018)Xue Zhang · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2025–2025)Xiaoqing Qian · Ningbo University1 papers (2025–2025)— · 1 papers (2025–2025)— · 1 papers (2025–2025)Mei Ding · National University of Singapore1 papers (2018–2018)Ryan Hicks · King's College London1 papers (2018–2018)